SCHEMBL4667572

SCHEMBL4667572

O=c1[nH]c(O)c(Cc2ccccc2)c(=O)[nH]1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TYMP P19971 1/20 0.65
ALDH1A1 P00352 5/20 0.61
MAPT P10636 3/20 0.61
KDM4A O75164 1/20 0.60
KDM4C Q9H3R0 1/20 0.60
KDM4E B2RXH2 2/20 0.55
NR3C1 P04150 5/20 0.52
NR3C2 P08235 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PKM P14618 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
ERAP1 Q9NZ08 1/20 0.47
DAO P14920 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20828256 0.79 TYMP (0.65) TYMPALDH1A1KDM4ENR3C1NR3C2
SCHEMBL2672214 0.79 TYMP (1.00) TYMPALDH1A1MAPTKDM4ENR3C1
SCHEMBL10857095 0.75 TYMP (0.59) TYMPALDH1A1KDM4ENR3C1NR3C2
Diphenylmethane SCHEMBL10711103 0.74 CALM1 (0.63) TYMPALDH1A1KDM4ENR3C1SMN1; SMN2
SCHEMBL5197218 0.72 TYMP (0.57) TYMPALDH1A1MAPTKDM4ENR3C1
SCHEMBL5313245 0.71 ALDH1A1 (1.00) ALDH1A1MAPTKDM4EPKMMEN1
SCHEMBL9353995 0.70 TYMP (0.54) TYMPALDH1A1MAPTKDM4AKDM4C
SCHEMBL17917621 0.70 HPGD (0.53) TYMPALDH1A1KDM4ENR3C1SMN1; SMN2
SCHEMBL12432451 0.70 KDM4E (0.53) TYMPALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL12611802 0.69 NR3C1 (1.00) NR3C1NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1491201-B1 Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides WELLSTAT THERAPEUTICS CORP (US) 2006-03-22 EP claimed
EP-0594667-B1 TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES PRO NEURON INC (US) 2001-09-19 EP claimed
EP-0526537-B1 5-BENZYL BARBITURATE DERIVATIVES UNIV BROWN RES FOUND (US) 1995-07-12 EP claimed
US-10031264-B2 Polarizing plate and display device FUJIFILM CORPORATION (JP) 2018-07-24 US disclosed
US-9817156-B2 Polarizing plate protective film, polarizing plate and display device FUJIFILM CORPORATION (JP) 2017-11-14 US disclosed
US-9817156-B2 Polarizing plate protective film, polarizing plate and display device FUJIFILM CORPORATION (JP) 2017-11-14 US disclosed
US-20170322358-A1 POLARIZING PLATE, FRONT PANEL OF DISPLAY DEVICE, DISPLAY APPARATUS, SUBSTRATE OF TOUCH PANEL, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL FUJIFILM CORPORATION (JP) 2017-11-09 US disclosed
US-20170322358-A1 POLARIZING PLATE, FRONT PANEL OF DISPLAY DEVICE, DISPLAY APPARATUS, SUBSTRATE OF TOUCH PANEL, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL FUJIFILM CORPORATION (JP) 2017-11-09 US disclosed
US-20170226317-A1 POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, AND DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2017-08-10 US disclosed
US-20170226317-A1 POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, AND DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2017-08-10 US disclosed
US-9678249-B2 Polarizing plate protective film, polarizing plate and display device FUJIFILM CORPORATION (JP) 2017-06-13 US disclosed
US-20150253479-A1 POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME FUJIFILM CORPORATION (JP) 2015-09-10 US disclosed
US-20150253479-A1 POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME FUJIFILM CORPORATION (JP) 2015-09-10 US disclosed
US-20140242300-A1 POLARIZER, POLARIZING PLATE USING THE SAME, LIQUID CRYSTAL DISPLAY DEVICE, AND METHOD OF MANUFACTURING POLARIZING PLATE FUJIFILM CORPORATION (JP) 2014-08-28 US disclosed
US-20140242300-A1 POLARIZER, POLARIZING PLATE USING THE SAME, LIQUID CRYSTAL DISPLAY DEVICE, AND METHOD OF MANUFACTURING POLARIZING PLATE FUJIFILM CORPORATION (JP) 2014-08-28 US disclosed
US-20140242302-A1 LAMINATE, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY DEVICE, AND METHOD OF MANUFACTURING POLARIZING PLATE FUJIFILM CORPORATION (JP) 2014-08-28 US disclosed
US-20140242302-A1 LAMINATE, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY DEVICE, AND METHOD OF MANUFACTURING POLARIZING PLATE FUJIFILM CORPORATION (JP) 2014-08-28 US disclosed
EP-1365755-B1 USE OF PYRIMIDINE NUCLEOSIDES AND/OR THE PRODRUGS THEREOF FOR COMBATING THE SIDE-EFFECTS OF HAART (HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY) AND OTHER ANTI-VIRAL THERAPIES PHARMA NORD APS (DK) 2008-10-22 EP disclosed
EP-1365755-A2 USE OF PYRIMIDINE NUCLEOSIDES AND/OR THE PRODRUGS THEREOF FOR COMBATING THE SIDE-EFFECTS OF HAART (HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY) AND OTHER ANTI-VIRAL THERAPIES Walker, Ulrich (DE) 2003-12-03 EP disclosed
WO-2002069943-A2 USE OF PYRIMIDINE NUCLEOSIDES AND/OR THE PRODRUGS THEREOF FOR COMBATING THE SIDE-EFFECTS OF HAART (HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY) AND OTHER ANTI-VIRAL THERAPIES WALKER ULRICH (DE) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226317-A1 POLARIZING PLATE PROTECTIVE FILM, POLARIZING PLATE, AND DISPLAY DEVICE NBAS, SSB, BIRC5 TYMP 4847/4885ALDH1A1 4014/4885MAPT 4098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.